Clene’s (CLNN) New Drug On Accelerated Approval Pathway: Benchmark

July 1, 2025 9:29 AM UTC Send to a Friend
In a note on Healthcare Technology, Benchmark provided an update for Clene Inc. (NASDAQ: CLNN).The analyst commented, “Clene says it ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login